How much does a box of Apelis cost? Price comparison at home and abroad and factors affecting drug prices

Alpelisib (Alpelisib) is a targeted therapy drug mainly used to treat PIK3CAgene mutation-positive HRpositive and HER2negative breast cancer. It is usually used as a second-line or third-line treatment drug. Since Apelvis is not yet available in the country, domestic patients cannot purchase it directly from China for the time being. For patients who need treatment, they usually obtain the drug through overseas purchasing or purchasing overseas.

At present, the price of Apelvis varies widely in different countries and regions. In India, the price of the original drug Apelvis is approximately more than 3,000 yuan (the specific price may vary depending on the region and supplier). This price is relatively expensive for domestic patients, especially if long-term use is required, which may bring a considerable financial burden. However, this price usually includes production, transportation, tariffs and other costs, and the R&D and production costs of original drugs are higher, so the price is more expensive.

In addition to the original drug, Apelvis also has generic versions on the market overseas. Compared with the original drug, the price of the generic version is more affordable, usually priced at around more than 1,000 yuan. Although generic drugs are basically the same as original drugs in terms of ingredients and efficacy, their market prices are usually lower due to lower production costs and no R&D and patent fees involved. For some patients with limited financial status, generic drugs have become a more feasible option, especially when they cannot afford the high cost of original drugs.

The main factors affecting the price difference of Apelis include research and development costs, patent protection, drug policies in production areas, and import tariffs. The research and development and patent protection of original drugs usually make them more expensive, while generic drugs make their prices more affordable by reducing R&D investment, lowering production costs and removing patent restrictions. With the advancement of relevant domestic approval procedures, the domestic version of Apelvis may be launched in the future, and the price may drop further by then, thereby providing more affordable treatment options for more patients.

Reference materials:https://www.piqray.com/